+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Armagen - logo

ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. ArmaGen’s headquarters and research operations are located in Calabasas, CA.

Mucopolysaccharidosis II Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Mucopolysaccharidosis II Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 94 Pages
  • Global
From
Rett Syndrome Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Rett Syndrome Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 89 Pages
  • Global
From
Metachromatic Leukodystrophy Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Metachromatic Leukodystrophy Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 77 Pages
  • Global
From
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 580 Pages
  • Global
From
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 73 Pages
  • Global
From
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 77 Pages
  • Global
From
Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • March 2019
  • 220 Pages
  • Global
From
Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injector and Wearable Infusion Pump), Usability, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Thumbnail Image

Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injector and Wearable Infusion Pump), Usability, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • August 2023
  • 664 Pages
  • Global
From
Rett Syndrome - Pipeline Review, H2 2020 - Product Thumbnail Image

Rett Syndrome - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 178 Pages
  • Global
From
N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021 - Product Thumbnail Image

N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 60 Pages
  • Global
From
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Drugs In Development, 2021 - Product Thumbnail Image

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 68 Pages
  • Global
From
Parkinson's Disease - Pipeline Review, H2 2020 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 1308 Pages
  • Global
From
Alpha L-Iduronidase - Pipeline Review, H2 2020 - Product Thumbnail Image

Alpha L-Iduronidase - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 66 Pages
  • Global
From
N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2020 - Product Thumbnail Image

N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 59 Pages
  • Global
From
Alpha N-Acetylglucosaminidase - Pipeline Review, H1 2020 - Product Thumbnail Image

Alpha N-Acetylglucosaminidase - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 54 Pages
  • Global
From
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2020 - Product Thumbnail Image

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 68 Pages
  • Global
From
Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030 - Product Thumbnail Image

Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030

  • Report
  • October 2019
  • 302 Pages
  • Global
From
Alzheimer's Disease - Pipeline Review, H2 2020 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 1785 Pages
  • Global
From
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 49 Pages
  • Global
From
Stroke - Pipeline Review, H2 2020 - Product Thumbnail Image

Stroke - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 773 Pages
  • Global
From
Loading Indicator